Form 10 Explorer
10-Q
Quarterly Report
Actuate Therapeutics, Inc.

ACTU

NASDAQ

CIK: 1652935

File #: 001-42139

Period End: Sep 30, 2025

Fiscal Year: 2025

View on EDGAR
Balance Sheet
31 line items · 2 periods
XBRL
ItemSep 30, 2025Dec 31, 2024
ASSETS
Current assets:
Cash and Cash Equivalents
16,924,7638,641,622
Other Non-Operating Current Assets
519,237566,278
Total current assets
17,444,0009,207,900
Other Non-Operating Non-Current Assets
269,934110,548
Total assets
17,713,9349,318,448
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts Payable
1,245,3751,921,189
Other Non-Operating Current Liabilities
4,259,0485,921,908
Other Current Liabilities
846,283888,449
Other Non-Operating Current Liabilities
21,95670,957
U I C License Agreement
70,957
Total current liabilities
6,372,6628,802,503
Long term liabilities:
Accrued interest, less current portion
06,768
U I C License Agreement
6,768
License payable
404,991404,991
Total long-term liabilities
404,991411,759
Total liabilities
6,777,6539,214,262
Stockholders’ equity:
Preferred Stock
00
Total Stockholders' Equity
2320
Total Stockholders' Equity
160,990,006132,484,015
Total Stockholders' Equity
(150,053,748)(132,379,849)
Total stockholders’ equity
10,936,281104,186
Common Stock
2320
Additional Paid-in Capital
160,990,006132,484,015
Retained Earnings
(150,053,748)(132,379,849)
Total liabilities and stockholders’ equity
17,713,9349,318,448